Bass, Berry & Sims attorney Shannon Wiley outlined the details of the Centers for Medicare & Medicaid Services (CMS) final rule on the Medicaid drug rebate program that goes into effect April 1, 2016. The article focuses on the new rule related to the determination of average manufacturer price (AMP). As stated in the article, “[o]n the issue of AMP calculation, the Final Rule addressed the use of the industry norm ‘presumed inclusion’ approach versus the proposed ‘buildup’ approach when calculating sales to wholesalers for drugs distributed to retail community pharmacies.”
The full article, “CMS Releases Final AMP Rule,” was published by the Life Sciences and Regulation, Accreditation, & Payment Practice Groups of the American Health Lawyers Association (AHLA) on February 1, 2016. The full article is available to members to the AHLA website.